September 10, 2019
Authored and Edited by Yieyie Yang, Ph.D.; Samhitha Muralidhar Medatia; Elizabeth D. Ferrill
In Allergan Sales, LLC v. Sandoz, Inc., No. 2018-2207 (Fed. Cir. Aug. 29, 2019), the Federal Circuit held that the “wherein” clauses in Allergan’s method-of-treatment claims are limiting. Claim 1 of the patent-at-issue recited topically administering a composition comprising 0.2% w/v brimonidine tartrate and 0.68% w/v timolol maleate, “wherein” the method is as effective as a 0.2% w/v brimonidine tartrate monotherapy, and “wherein” the method reduces the incidence of one or more specified adverse effects compared to the 0.2% w/v brimonidine tartrate monotherapy.
The court found that the specification demonstrated that the claimed invention was ultimately a formulation (and methods of using that formulation) that allowed for increased efficacy and safety. The Federal Circuit reasoned that those benefits, instead of merely being intended purposes, were believed by Allergan to be material to patentability.
The Federal Circuit also noted that Allergan relied on the efficacy and safety of the claimed methods during prosecution in response to the examiner’s rejections and that the Examiner explicitly relied on the “wherein” clauses in explaining why the claims were “novel and non-obvious over the prior art” in the Notice of Allowance. Accordingly, the Federal Circuit concluded that the intrinsic evidence supported that the “wherein” clauses were material to patentability and thus limiting.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.